Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Most common Jardiance (empagliflozin) side effects, such as increased urination, mild dehydration, thirst, and dizziness, tend to ease within the first few days to a few weeks as your body adjusts, while genital yeast or urinary tract infections usually clear once treated. Timelines vary by dose, kidney function, hydration, and other medications you take, and some effects can persist or signal something more serious that needs prompt attention. There are several important factors and warning signs to consider, including symptoms that should never be waited out. See below to understand more about typical durations, when to call your doctor, and what may help symptoms resolve faster. If your symptoms are lingering longer than expected or you are unsure whether they are normal adjustment effects, a free, instant, online symptom check can help you sort out possible causes in minutes and guide your next steps before your next appointment.
Last reviewed for medical accuracy: 09/13/2026
Jardiance (empagliflozin) is a once-daily pill used to help control blood sugar in people with type 2 diabetes. Like any medication, it can cause side effects. Knowing how long these side effects might last can help you feel more confident and prepared when you start treatment.
Jardiance works by blocking a protein in your kidneys (the SGLT2 transporter) so excess glucose is removed through urine. As your body adjusts to this new way of handling sugar, you may notice changes in how you feel. Most side effects occur as your system adapts, then subside.
Though everyone is different, here’s a general idea of how long common side effects last:
First Few Days (1–3 days)
• Increased urination and mild dehydration—your body is flushing out more glucose and fluid.
• Slight dizziness or lightheadedness when standing.
First 1–2 Weeks
• Headache, mild nausea or stomach upset as your body adjusts.
• Increased thirst—compensating for fluid loss.
• Possible drop in blood pressure (feeling a bit tired or weak).
Weeks 2–4
• Most dehydration-related effects (thirst, dizziness) usually improve as you find the right fluid balance.
• Your kidneys and bladder settle into the new routine, so bathroom visits may normalize.
• If you’re prone to yeast infections or urinary tract infections (UTIs), these may appear, often within the first month.
After 1 Month
• Many early side effects resolve completely.
• Risk of genital infections and UTIs remains somewhat elevated as long as you take Jardiance—maintaining good hygiene and hydration is key.
• Ongoing monitoring for rare but serious effects (such as ketoacidosis) continues.
Most side effects of Jardiance fade as your body adapts. However, you should contact your doctor or seek medical help if you experience:
For a free, online symptom check, using the doctor approved Ubie Symptom Checker can help you decide what steps to take next and when to call a professional.
Understanding what to expect can make starting Jardiance smoother. Most “jardiance side effects” are temporary and improve within a few weeks. Some, like infection risk, persist at a lower level and can be managed with good habits and prompt treatment.
Always discuss any new or worsening symptoms with your doctor—particularly if they’re severe or life-threatening. Your healthcare team can adjust your treatment, recommend remedies, or arrange tests to keep you safe and comfortable.
If you’re uncertain about what you’re feeling, try a free, online symptom check, using the doctor approved Ubie Symptom Checker, then speak directly with your doctor about any serious concerns. Never hesitate to seek immediate help if you believe you’re experiencing a medical emergency.
(References)
* Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.
* Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. PMID: 27299675.
* Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. PMID: 35228754; PMCID: PMC8938265.
* The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.
* Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6. PMID: 38587237.
* Lava SAG, Laurence C, Di Deo A, Sekarski N, Burch M, Della Pasqua O. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review. Paediatr Drugs. 2024 May;26(3):229-243. doi: 10.1007/s40272-024-00623-z. Epub 2024 Apr 18. PMID: 38635113.
* Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. Epub 2024 May 1. PMID: 38696170; PMCID: PMC11066699.
* Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Adv Ther. 2024 Jul;41(7):2826-2844. doi: 10.1007/s12325-024-02879-w. Epub 2024 May 21. PMID: 38771475; PMCID: PMC11213770.
* Khan S, Broce A. Empagliflozin-induced Myopathy. JCEM Case Rep. 2024 Dec;2(12):luae216. doi: 10.1210/jcemcr/luae216. Epub 2024 Nov 28. PMID: 39611184; PMCID: PMC11604052.
* Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M, CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. PMID: 40470996.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.